Emerging therapies targeting the ubiquitin proteasome system in cancer
about
The cilia-regulated proteasome and its role in the development of ciliopathies and cancerThe Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant RecipientsA Decade of Boon or Burden: What Has the CHIP Ever Done for Cellular Protein Quality Control Mechanism Implicated in Neurodegeneration and Aging?Tackling Cancer Stem Cells via Inhibition of EMT Transcription FactorsTrial Watch: Proteasomal inhibitors for anticancer therapyIdentification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data.Mechanistic insights into the impact of Cold Atmospheric Pressure Plasma on human epithelial cell lines.In silico functional analyses and discovery of survival-associated microRNA signatures in pediatric osteosarcoma.Mechanism of substrate translocation by a ring-shaped ATPase motor at millisecond resolutionThe Proapoptotic F-box Protein Fbxl7 Regulates Mitochondrial Function by Mediating the Ubiquitylation and Proteasomal Degradation of SurvivinThe Human IL-22 Receptor Is Regulated through the Action of the Novel E3 Ligase Subunit FBXW12, Which Functions as an Epithelial Growth Suppressor.Inhibition on Proteasome β1 Subunit Might Contribute to the Anti-Cancer Effects of Fangchinoline in Human Prostate Cancer Cells.Inhibition of SCF ubiquitin ligases by engineered ubiquitin variants that target the Cul1 binding site on the Skp1-F-box interface.A Founder Mutation in VPS11 Causes an Autosomal Recessive Leukoencephalopathy Linked to Autophagic DefectsDisease-proportional proteasomal degradation of missense dystrophinsF-box protein Fbxl18 mediates polyubiquitylation and proteasomal degradation of the pro-apoptotic SCF subunit Fbxl7A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice.Mortality factor 4 like 1 protein mediates epithelial cell death in a mouse model of pneumoniaSmall molecule therapeutics targeting F-box proteins in cancer.Expression of immunoproteasome genes is regulated by cell-intrinsic and -extrinsic factors in human cancersNew molecular targets for the treatment of sarcoidosis.Regulation of histone modifying enzymes by the ubiquitin-proteasome system.Recent advances and future directions in targeting the secretory apparatus in multiple myeloma.When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response.SCFFBXO17 E3 ligase modulates inflammation by regulating proteasomal degradation of glycogen synthase kinase-3β in lung epithelia.Highly Multiplexed Quantitative Mass Spectrometry Analysis of Ubiquitylomes.Acid-labile boronate-bridged dextran-bortezomib conjugate with up-regulated hypoxic tumor suppression.Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target.Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cells.Decoding the growth advantage of hypoxia-sensitive lung cancer.An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons.Significance of the E3 ubiquitin protein UBR5 as an oncogene and a prognostic biomarker in colorectal cancer.Active site-targeted covalent irreversible inhibitors of USP7 impair the functions of Foxp3+ T-regulatory cells by promoting ubiquitination of Tip60.Mouse models of two missense mutations in actin binding domain 1 of dystrophin associated with Duchenne or Becker muscular dystrophy.Conserved structural and functional aspects of the tripartite motif gene family point towards therapeutic applications in multiple diseases.Ginkgolic acid, a sumoylation inhibitor, promotes adipocyte commitment but suppresses adipocyte terminal differentiation of mouse bone marrow stromal cells.MCM3AP and POMP Mutations Cause a DNA-Repair and DNA-Damage-Signaling Defect in an Immunodeficient Child.Investigation of genetic variants in ubiquitin enzyme genes involved in the modulation of neurodevelopmental processes: a role in schizophrenia susceptibility?The Human Replicative Helicase, the CMG Complex, as a Target for Anti-cancer Therapy.Synthesis of a Bone-Targeted Bortezomib with In Vivo Anti-Myeloma Effects in Mice
P2860
Q26746930-D7B16701-380B-4B59-87E3-29BC971AF137Q26774993-0682CCDB-3B84-483E-A4AB-9C7DA420688BQ28078724-A77B8BA3-EB7A-4601-95B5-AC32E9635B7DQ28079863-9699171A-E2C9-420A-A4F0-01ED85AA5F3AQ28082910-9C76F23B-303D-4301-A714-2F069AB06BF4Q31134060-F1F43A47-E961-435D-ADD6-620C081679E5Q33469694-8820E8B8-849A-4667-895B-F204C37193BFQ34781386-B92B883F-A097-4D3C-B753-7AD4BFE39154Q35372059-094830D8-A89A-483B-B47B-42923CD8301DQ35583027-87EF1C81-A3EA-4504-884C-404DB3DA91F5Q35782202-5B8CF0DD-79E1-461E-9ACB-85BC087622E6Q35825885-CB52B2E7-9312-4626-9079-1ECE52000E81Q35956904-94B4C473-9F5C-4A29-B982-CDDBF16943DDQ36000935-C61AF878-0870-40C5-825B-DCEA4D58D32EQ36155218-A1CD7D68-8E3A-4F68-8878-A6493888087DQ36347238-D2AC17BD-D5AE-4A48-87AB-20DB14D04C55Q36356398-510736F4-C6BD-4DB9-8F9E-BD76A34571FEQ36593428-E1182B96-58D5-4D46-B47C-45E3C595AB2FQ36600976-AF6F8F54-49A0-434D-9DAB-5AB455EE973FQ37278032-1646A0AB-0888-43FF-AE9F-3311B0B11431Q37494750-6BF46A8E-2EF6-4E29-AB72-7365FEBA90E0Q37664744-BE6953E6-2BFB-46D6-A460-381908038908Q38258197-62DEF189-3BC3-4BA8-BE23-1EB3BE401C7CQ38503345-8058D378-6AAD-45C6-B94C-F3A0F7321C85Q38712145-F35F8FD9-AE7C-4B55-9D3F-42A9AC0B5754Q38736515-3A67EFCF-9B95-4BE3-BE8A-A01739C2E0BCQ38897881-1A11135A-7F02-41C9-87EA-4163C5A3452EQ41083946-15B0F64C-C22A-45C4-AA28-7EA2A6A5A5E0Q41214052-5F7F32CD-5B53-4B68-9D3A-C72532A1AE3FQ42968461-2FD97489-64C8-4BCD-9151-EC8A99623922Q46916073-00176FD5-C859-4B06-A019-ABF98864CE73Q47128996-E0768B89-CC03-4480-B397-4E02ACECC790Q47135501-33497DC8-15BA-4539-A262-CFF49A5C48F4Q47342349-27E1B198-84CF-4F00-8B50-F8EA2AC1A75AQ47448021-5A958D5A-B16A-4E6D-AF42-0472B670C9C2Q50130005-6561A120-AAB1-4DF1-B90E-ECE0C02EAB54Q50434602-CC9EBE14-E8F0-419B-B1CC-797DA91766B7Q50608185-3411BC08-D264-478F-9698-25F0D6C4E3E1Q52322877-4091CF80-59D1-4FDC-91AD-5C0B10A383C1Q58753490-7D2F7835-DC02-4329-BE7D-B0A0C21C57BD
P2860
Emerging therapies targeting the ubiquitin proteasome system in cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging therapies targeting the ubiquitin proteasome system in cancer
@en
Emerging therapies targeting the ubiquitin proteasome system in cancer.
@nl
type
label
Emerging therapies targeting the ubiquitin proteasome system in cancer
@en
Emerging therapies targeting the ubiquitin proteasome system in cancer.
@nl
prefLabel
Emerging therapies targeting the ubiquitin proteasome system in cancer
@en
Emerging therapies targeting the ubiquitin proteasome system in cancer.
@nl
P2860
P356
P1476
Emerging therapies targeting the ubiquitin proteasome system in cancer
@en
P2093
Nathaniel M Weathington
Rama K Mallampalli
P2860
P356
10.1172/JCI71602
P407
P577
2014-01-02T00:00:00Z